Incyte Corporation

Merus N.v.

Rebecca A Buonpane

Horacio G Nastri

Shaun M Stewart

Jing Zhou

Wenqing Yao

Liangxing Wu

Xiaozhao Wang

Wenyu Zhu

Taisheng Huang

Chao Qi

Peter Niels Carlsen

Yingnan Chen

Yong Li

Patrick Mayes

Hui Wang

Simon Edward Plyte

Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.

CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy

Anti-CD73 antibodies are disclosed. Also disclosed are related nucleic acids, vectors, cells, and pharmaceutical compositions. Methods of treating cancer with the anti-CD73 antibodies are also disclosed.

Anti-CD73 antibodies and uses thereof

The present disclosure relates to novel PD-1 binding domains that have a higher binding affinity for human PD-1 than a reference PD-1 binding domain. The PD-1 binding domains of the present disclosure further provide a comparable, or equal or higher, potency in blocking ligand binding to human PD-1 than a reference PD-1 antibody. The present disclosure further relates to binding moieties comprising such PD-1 binding domains. Also provided is a method for treating a disease, in particular a disease associated with a suppressed immune system, such as cancer, with a PD-1 binding domain or binding moiety of the present disclosure. The present disclosure further relates to nucleic acids encoding the heavy chain variable region of the PD-1 binding domains, and a vector and cell comprising such nucleic acid.

PD-1 binding domains

Growing community of inventors

Wilmington, DE, United States of America

Rebecca A Buonpane